Highlights

Highlights

  • 02.03.2026 – 17:45

    Cornèr Banca SA

    Cornèr Banca SA: The Cornèr Group reaffirms its solidity

    The Cornèr Group reaffirms its solidity

    Lugano (ots) - The Cornèr Group delivered positive results in 2025, underpinned by its client base and the consistency of its business model. The trust placed in the Group translated into further growth in deposits, which reached CHF 5,454.4 million (+ 5.4%), and an expansion of lending activities, particularly in the mortgage segment. The 74th financial year closed with a balance sheet total close to CHF 9 billion (+ 3.1%), liquidity of CHF 904 million, largely held with the Swiss National Bank, and capital resources amounting to CHF 1,255.8 million (+ 2.7%). Revenues amounted to CHF 470.8 ...

    Un document

Actualités

Filtre
  • 25.01.2019 – 09:01

    ZENTIVA Pharma GmbH

    Zentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment

    Prague (ots/PRNewswire) - Zentiva is investing EUR 30 million to maximize its manufacturing site capabilities in Prague. The investment further strengthens Zentiva's manufacturing footprint and is part of a broader ambition to become the champion of generics in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) Thomas Koene, Head of Industrial ...

  • 24.01.2019 – 15:07

    TetraPak

    New Tetra Pak CEO Appointed

    Pully, Switzerland (ots/PRNewswire) - The Tetra Laval Group Board has appointed Mr Adolfo Orive, President & CEO of Tetra Pak effective April 1, 2019. The appointment follows the decision by Mr Dennis Jönsson to step down from his position after 14 years as President & CEO and 36 years with the company. (Logo: https://mma.prnewswire.com/media/813029/Tetra_Laval_Logo.jpg ) (Photo: https://mma.prnewswire.com/media/813041/Tetra_Pak_Adolfo_Orive.jpg ) Adolfo Orive, presently ...

  • 24.01.2019 – 14:01

    Merck Healthcare Germany

    Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

    Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology - Merck retains the rights to utilize and ...

  • 23.01.2019 – 16:02

    Philogen

    Philogen Announces Collaboration With Celgene

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development ...

  • 23.01.2019 – 16:01

    Philogen

    Philogen Announces Collaboration

    Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...